A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

NCT04931459 | Completed Phase 1 DMC FDA Drug

• 2 other identifiers: ACU-0013U01AG053247
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 17

Brief Summary

This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer's disease (AD).

Conditions

Alzheimer Disease

Keywords

Alzheimer's Diseases; Mild Cognitive Impairment; Mild dementia

Outcome Measures

Primary Outcomes (5)

• Incidence and Nature of Treatment-Related Adverse Events (AE) or Serious Adverse Events (SAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)

  Proportion of participants with AE, discontinuations due to AE or SAE, and withdrawals from the study due to AE

  Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)

• Change in Clinical Laboratory Tests

  Incidence and clinically significant abnormal changes in clinical laboratory assessments (hematology, clinical chemistry, urinalysis)

  Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)

• Changes in 12-Lead ECGs

  Clinically significant abnormal changes in 12-Lead ECGs for PR, QRS, QT, QTcF, and QTcB

  Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)

• Changes in the Columbia-Suicide Severity Rating Scale (C-SSRS)

  Presence of suicidal ideation as defined by a positive response to Question 5 on the C-SSRS suicide ideation section

  Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)

• Changes in Magnetic Resonance Imaging (MRI)

  Brain magnetic resonance imaging (MRI) findings to assess amyloid-related imaging abnormalities (ARIA), including incidence of ARIA-E (edema) or ARIA-H (hemosiderosis)

  Baseline (predose) up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)

Secondary Outcomes (6)

• Estimate Blood Levels of ACU193

  Up to 140 days post dose

• Estimate Maximum Blood Levels of ACU193

  Up to 140 days post dose.

• Estimate Time to Reach Maximum Blood Levels of ACU193

  Up to 140 days post dose.

• Estimate Blood Levels of ACU193

  Up to 140 days post dose.

• Estimate Clearance of ACU193

  Up to 140 days post dose

Study Arms (2)

ACU193 Administration

EXPERIMENTAL

Participants will receive 1 to 3 doses of ACU193 by intravenous (IV) infusion.

Drug: ACU193

Placebo Administration

PLACEBO COMPARATOR

Participants receive 1 to 3 doses of matching ACU193 placebo by intravenous (IV) infusion. 2 participants per cohort will receive placebo.

Drug: Placebo

Interventions

ACU193 DRUG

Intravenous ACU193

ACU193 Administration

Placebo DRUG

Intravenous Placebo

Placebo Administration

Eligibility Criteria

• Age: 55 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females ages 55 to 90 (inclusive).
• Participant weighs at least 41 kg (90 lbs) and no more than 113 kg (250 lbs) before study drug administration.
• Female participants must be surgically sterile or be at least two years post-menopausal or at least one year post-menopausal with an elevated follicle stimulating hormone (FSH). Male participants with a female partner of child-bearing potential must use adequate contraception.
• Individual (or the participant's Legally Authorized Representative \[LAR\]) is able to give informed consent.
• Are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• Must meet all of the following clinical criteria for MCI due to AD or mild AD at Screening:
• Participant meets NIA-Alzheimer's Association (NIA-AA) criteria for MCI due to AD or probable AD.
• A global Clinical Dementia Rating (CDR) of 0.5 or 1.0.
• A Mini-Mental State Examination (MMSE) score between 18 and 30 (inclusive).
• A positive amyloid positron emission tomography (PET) scan.
• Must consent to apolipoprotein E (APOE) genotyping.
• If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least four weeks prior to Baseline and the participant must be willing to keep the doses stable throughout the duration of the study.
• Must have a reliable informant or caregiver who is willing and able to perform all caregiver roles as specified in the caregiver Informed Consent Form (ICF).

You may not qualify if:

• Receipt of any investigational biological drug within less than one year of Baseline or of any investigational small molecule drug within less than six months of Baseline. Receipt of any approved treatments that target amyloid plaques in the brain within less than one year of Baseline.
• Currently receiving or likely to require the following types of anticoagulants: coumarins and indandiones, Factor Xa inhibitors, heparins, thrombin inhibitors.
• Has known humanized monoclonal antibody allergy or hypersensitivity.
• History of significant neurological disease, other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson´s disease, or adult epilepsy.
• Has had magnetic resonance imaging (MRI) or computerized tomography (CT) of brain within previous two years showing pathology that would be inconsistent with a diagnosis of AD.
• Has MRI with results showing greater than four amyloid-related imaging abnormalities hemorrhage/hemosiderin deposition (ARIA-H), presence of any amyloid-related imaging abnormalities edema/effusions (ARIA-E), or superficial siderosis.
• Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI.
• Current serious or unstable clinically important illness that, in the judgment of the Investigator, is likely to affect cognitive assessment including visual and hearing impairment, deteriorate, or affect the participant's safety or ability to complete the study, including psychiatric, hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrinological, immunologic, or hematologic disorders.
• Has an ongoing or new clinically significant laboratory abnormality, as determined by the Investigator.
• Has a history or presence of clinically significant abnormal 12-lead electrocardiogram (ECG) or an ECG with QT interval corrected using Fridericia's formula (QTcF) \>470 msec for female participants or \>450 msec for male participants. As the ECGs are obtained in triplicate and are meant to be interpreted together, if one of the three ECGs in the triplicate has a QTcF above the threshold, eligibility of the participant should be determined based on clinical judgment of the Investigator in consultation with the medical monitor. If two of the three ECGs in the triplicate have a QTcF above the threshold, then the participant would not be eligible.
• Within one year before Screening, any of the following: myocardial infarction; moderate or severe congestive heart failure, New York Heart Association class III or IV; hospitalization for, or symptom of, unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known significant structural heart disease (eg, significant valvular disease, hypertrophic cardiomyopathy), or hospitalization for arrhythmia.
• History of seizure, transient ischemic attack (TIA), or stroke within the last 18 months.
• History of clinically significant carotid or vertebrobasilar stenosis or plaque.
• History of a malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen posttreatment within the last five years.
• Current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the Investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study.

Sponsors & Collaborators

• Acumen Pharmaceuticals: lead
• National Institute on Aging (NIA): collaborator

Study Sites (17)

Clinical Endpoints

Scottsdale, Arizona, 85258, United States

Location

Orange County Research Institute

Anaheim, California, 92801, United States

Location

Hoag Hospital Newport Beach

Newport Beach, California, 92663, United States

Location

Velocity Clinical Research

Hallandale, Florida, 33009, United States

Location

Charter Research

Lady Lake, Florida, 32159, United States

Location

Columbus Clinical Services

Miami, Florida, 33125, United States

Location

Combined Research Orlando Phase I-IV

Orlando, Florida, 32807, United States

Location

Progressive Medical Research

Port Orange, Florida, 32321, United States

Location

Santos Research Center

Tampa, Florida, 33615, United States

Location

Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States

Location

iResearch Atlanta

Decatur, Georgia, 30030, United States

Location

Advanced Memory Research Institute of NJ

Toms River, New Jersey, 08755, United States

Location

Columbia University

New York, New York, 10032, United States

Location

AMC Research

Matthews, North Carolina, 28105, United States

Location

Abington Neurological Associates

Abington, Pennsylvania, 19001, United States

Location

Kerwin Medical Center

Dallas, Texas, 75231, United States

Location

Clinical Trials Network

Houston, Texas, 77074, United States

Location

MeSH Terms

Conditions

Alzheimer Disease; Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Cognition Disorders

Study Officials

• Eric Siemers, MD

  Acumen Pharmaceuticals, Inc.

  PRINCIPAL INVESTIGATOR

• Russell Barton

  Acumen Pharmaceuticals, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Study ACU-001 is a placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple escalating doses of intravenous ACU193. A two-part single-ascending dose (SAD)/multiple-ascending dose (MAD) study design will be conducted in a population of individuals with early AD (MCI or mild dementia due to AD).

Study Record Dates

• First Submitted: May 18, 2021
• First Posted: June 18, 2021
• Study Start: June 21, 2021
• Primary Completion: June 12, 2023
• Study Completion: June 12, 2023
• Last Updated: July 19, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (17)